NHS should fund GSK's £526,000 "bubble baby" drug - NICE

07:09 EST 3 Jan 2018 | pharmaphorum

NICE has recommended that the NHS should fund GlaxoSmithKline’s Strimvelis gene therapy for the extremely rare immune deficiency condition known as ‘bubble baby syndrome’. Costing €594,000 (£526,000) Strimvelis is the most expensive therapy cleare...

Original Article: NHS should fund GSK's £526,000 "bubble baby" drug - NICE


More From BioPortfolio on "NHS should fund GSK's £526,000 "bubble baby" drug - NICE"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...